MIM
STOK icon

MetLife Investment Management’s Stoke Therapeutics STOK Stock Holding History

MetLife Investment Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$850K Buy
26,106
+786
+3% +$25.8K ﹤0.01% 1479
2025
Q4 		$804K Hold
25,320
– – ﹤0.01% 1553
2025
Q3 		$595K Buy
25,320
+1,457
+6% +$25K ﹤0.01% 1721
2025
Q2 		$271K Buy
23,863
+3,609
+18% +$34.3K ﹤0.01% 2017
2025
Q1 		$135K Sell
20,254
-551
-3% -$5.14K ﹤0.01% 2391
2024
Q4 		$229K Hold
20,805
– – ﹤0.01% 2235
2024
Q3 		$256K Hold
20,805
– – ﹤0.01% 2156
2024
Q2 		$281K Buy
20,805
+12,521
+151% +$169K ﹤0.01% 2039
2024
Q1 		$112K Sell
8,284
-6,332
-43% -$38.4K ﹤0.01% 2479
2023
Q4 		$76.9K Hold
14,616
– – ﹤0.01% 2708
2023
Q3 		$57.6K Hold
14,616
– – ﹤0.01% 2809
2023
Q2 		$155K Buy
14,616
+2,995
+26% +$31.9K ﹤0.01% 2415
2023
Q1 		$96.8K Hold
11,621
– – ﹤0.01% 2567
2022
Q4 		$107K Hold
11,621
– – ﹤0.01% 2567
2022
Q3 		$149K Hold
11,621
– – ﹤0.01% 2460
2022
Q2 		$154K Hold
11,621
– – ﹤0.01% 2479
2022
Q1 		$245K Buy
11,621
+4,289
+58% +$85.9K ﹤0.01% 2232
2021
Q4 		$176K Hold
7,332
– – ﹤0.01% 2135
2021
Q3 		$187K Hold
7,332
– – ﹤0.01% 2138
2021
Q2 		$247K Buy
7,332
+1,855
+34% +$65.6K ﹤0.01% 2023
2021
Q1 		$213K Hold
5,477
– – ﹤0.01% 2021
2020
Q4 		$339K Sell
5,477
-2,335
-30% -$107K ﹤0.01% 1691
2020
Q3 		$262K Hold
7,812
– – ﹤0.01% 1695
2020
Q2 		$186K Hold
7,812
– – ﹤0.01% 1953
2020
Q1 		$179K Buy
7,812
+3,050
+64% +$75.4K ﹤0.01% 1765
2019
Q4 		$135K Buy
+4,762
New +$120K ﹤0.01% 2184

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

MetLife Investment Management's STOK Position: Q1 2026 in Review

MetLife Investment Management increased its Stoke Therapeutics (STOK) stake by 3.1% in Q1 2026, buying an estimated $25.8K and bringing the position to 26,106 shares worth $850K. The position accounts for ﹤0.01% of the portfolio, ranked #1479.

MetLife Investment Management first reported a position in STOK in Q4 2019 and has held it in 26 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • MetLife Investment Management held 26,106 shares of Stoke Therapeutics worth $850K as of Q1 2026.
  • MetLife Investment Management bought 786 Stoke Therapeutics shares in Q1 2026, an estimated $25.8K.
  • Stoke Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1479 holding.
  • MetLife Investment Management first reported a position in Stoke Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.